Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
HonorHealth Research Institute
Patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin will experience hair preservation with the use of the Paxman scalp cooling device, at the end of three, 3 week cycles of chemotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide written informed consent/assent for the trial
\>18 years of age on day of signing informed consent
Diagnosis of pancreatic cancer and scheduled to receive treatment with a regimen containing nab-paclitaxel, gemcitabine and cisplatin
You may not be if
Grade 1 alopecia
Existing history of scalp metastases or the presence of scalp metastases is suspected
No history of previous cancers within the past 5 years
Central Nervous System (CNS) malignancies (either primary or metastatic)
